Gynex Pharmaceuticals
Executive Summary
Acquires exclusive U.S. rights to Bristol-Myers Squibb's Delatestryl injectable testosterone for the treatment of hypogonadism in men and delayed puberty in boys, under an agreement announced March 30. Gynex says it will begin marketing the product "in mid-year 1992." BMS will manufacture the drug for Gynex for up to five years.